Not a good buy right now: trend is decisively bearish (SMA_200 > SMA_20 > SMA_5) and the stock is trading like a distressed micro-cap (~$0.76) with poor fundamentals.
While RSI (~24) suggests a near-term oversold bounce is possible, there is no proprietary “must-buy” signal today and negative headlines (class actions) dominate sentiment.
For an impatient buyer unwilling to wait for cleaner setups, the risk/reward is unfavorable versus the limited upside to nearby resistance (~$0.86–$0.97).
Momentum: MACD histogram is negative (-0.0136) but contracting (selling pressure is easing, not reversing yet).
RSI: RSI_6 at ~24.4 is oversold (often supports a short-term bounce), but oversold can persist in strong downtrends.
Key levels: Immediate support S1 ~0.746 (price ~0.758 pre-market is sitting on it). If it breaks, next support S2 ~0.676. Resistance levels: Pivot ~0.86, then R1 ~0.974.
Pattern-based odds: Model suggests ~70% chance of a small dip next day (-0.64%) but better odds of a rebound over 1 week (+2.77%) and 1 month (+5.07%)—counter-trend bounce potential, not a confirmed trend change.
Positioning/Sentiment: Put-call ratios are low (call-skewed), implying speculative bullishness or short-covering expectations despite the weak chart.
Volatility: Extremely elevated (HV ~456%, 30D IV ~159%; IV percentile 68) → market is pricing large moves; option prices are rich.
Activity: Today’s option volume is elevated vs average (today vs 30D avg ~11.7x), signaling heightened event/flow interest rather than calm accumulation.
Technical Summary
Sell
8
Buy
7
Positive Catalysts
near support (~0.
can trigger short-term bounce attempts.
on 2026-02-26 after hours could create a tradable catalyst (win or lose).
Neutral/Negative Catalysts
keep pressure on the name.
opens room toward ~0.
No supportive institutional/insider momentum noted (hedge funds/insiders described as neutral).
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: $70.22M, down -13.32% YoY (continued top-line contraction).
Profitability: Net income -$110.69M (still deeply negative; the YoY “increase” indicates larger losses vs prior year), EPS -1.44 (still sharply negative).
Margins: Gross margin 10.3%, down -41.68% YoY—deteriorating unit economics and weak pricing power.
Overall: Fundamentals do not yet support a durable bullish thesis; any upside is more likely a tactical bounce than a quality turnaround move.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent changes are negative: Barclays cut PT to $1 (from $2) and reiterated Underweight; Mizuho cut PT to $1 (from $1.50) and reiterated Underperform (post Q3).
Wall Street “pros” view: potential for a depressed-price rebound if execution improves and category stabilizes.
Wall Street “cons” view (dominant): weak category demand, competitive pricing pressure, and growth risks skewed to the downside—reflected in repeated target cuts and bearish ratings.
Wall Street analysts forecast BYND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BYND is 0.93 USD with a low forecast of 0.8 USD and a high forecast of 1 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast BYND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BYND is 0.93 USD with a low forecast of 0.8 USD and a high forecast of 1 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
3 Sell
Moderate Sell
Current: 0.666
Low
0.8
Averages
0.93
High
1
Current: 0.666
Low
0.8
Averages
0.93
High
1
Mizuho
Underperform
downgrade
$1
AI Analysis
2025-11-13
Reason
Mizuho
Price Target
$1
AI Analysis
2025-11-13
downgrade
Underperform
Reason
Mizuho lowered the firm's price target on Beyond Meat to $1 from $1.50 and keeps an Underperform rating on the shares post the Q3 report. The firm says that with U.S. demand for animal meat at multi-decade highs, and pricing from plant-based meat peers becomes more competitive, Beyond Meat's risks to growth remain skewed to the downside.
Barclays
Benjamin Theurer
Underweight
downgrade
$2 -> $1
2025-11-12
Reason
Barclays
Benjamin Theurer
Price Target
$2 -> $1
2025-11-12
downgrade
Underweight
Reason
Barclays analyst Benjamin Theurer lowered the firm's price target on Beyond Meat to $1 from $2 and keeps an Underweight rating on the shares. The company reported "another quarter of declines and a muted outlook," the analyst tells investors in a research note. The firm says category demand remains weak for plant-based meat.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for BYND